Ascendis Pharma AS (NASDAQ:ASND) dropped 1.2% during mid-day trading on Friday . The company traded as low as $19.39 and last traded at $19.40, with a volume of 135,386 shares trading hands. The stock had previously closed at $19.64.

A number of brokerages recently commented on ASND. Zacks Investment Research downgraded Ascendis Pharma AS from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th. Leerink Swann reissued an “outperform” rating and issued a $24.00 price target on shares of Ascendis Pharma AS in a report on Thursday, May 26th.

The company’s 50-day moving average price is $15.50 and its 200 day moving average price is $15.87. The firm’s market capitalization is $487.48 million.

Ascendis Pharma AS (NASDAQ:ASND) last posted its earnings results on Wednesday, August 31st. The company reported ($0.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. On average, analysts forecast that Ascendis Pharma AS will post ($3.34) EPS for the current fiscal year.

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.